Network Pharmacology and Experimental Validation Identify Paeoniflorin as a Novel SRC-Targeted Therapy for Castration-Resistant Prostate Cancer
Pharmaceuticals · 21.08.2025 · 18 (8) · 1241
DOI: 10.3390/ph18081241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 21.08.2025. Verfasst von Meng-Yao Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Despite advances in prostate cancer treatment, castration-resistant prostate cancer (CRPC) remains clinically challenging due to inherent therapy resistance and a lack of durable alternatives. Although traditional Chinese medicine offers untapped potential, the therapeutic role of paeoniflorin (Pae), a bioactive compound derived from Paeonia lactiflora, in prostate cancer has yet to be investigated.
Methods
Using an integrative approach (network pharmacology, molecular docking, and experimental validation), we identified Pae key targets, constructed protein–protein interaction networks, and performed GO/KEGG pathway analyses. A Pae-target-based prognostic model was developed and validated. In vitro and in vivo assays assessed Pae effects on proliferation, migration, invasion, apoptosis, and tumor growth.
Results
Pae exhibited potent anti-CRPC activity, inhibiting cell proliferation by 60% and impairing cell migration by 65% compared to controls. Mechanistically, Pae downregulated SRC proto-oncogene, non-receptor tyrosine kinase (SRC) mRNA expression by 68%. The Pae-target-based prognostic model stratified patients into high- and low-risk groups with distinct survival outcomes. Organoid and xenograft studies confirmed Pae-mediated tumor growth inhibition and SRC downregulation.
Conclusions
Pae overcomes CRPC resistance by targeting SRC-mediated pathways, presenting a promising therapeutic strategy. Our findings underscore the utility of network pharmacology-guided drug discovery and advocate for further clinical exploration of Pae in precision oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
ORCID-Profile: Meng-Yao Xu, Zhi-Hua Wang, Sheng Ma
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xu, M. Y., Zhang, J. B., Peng, Y. Z., Liu, M. C., Ma, S. Y., Zhou, Y., Wang, Z. H., & Ma, S. (2025). Network Pharmacology and Experimental Validation Identify Paeoniflorin as a Novel SRC-Targeted Therapy for Castration-Resistant Prostate Cancer. Pharmaceuticals, 18(8), 1241. https://doi.org/10.3390/ph18081241
Vancouver
Xu MY, Zhang JB, Peng YZ, Liu MC, Ma SY, Zhou Y, et al. Network Pharmacology and Experimental Validation Identify Paeoniflorin as a Novel SRC-Targeted Therapy for Castration-Resistant Prostate Cancer. Pharmaceuticals. 2025;18(8):1241. doi:10.3390/ph18081241
BibTeX
@article{Xu2025,
author = {Xu, Meng-Yao and Zhang, Jun-Biao and Peng, Yu-Zheng and Liu, Mei-Cheng and Ma, Si-Yang and Zhou, Ye and Wang, Zhi-Hua and Ma, Sheng},
title = {Network Pharmacology and Experimental Validation Identify Paeoniflorin as a Novel SRC-Targeted Therapy for Castration-Resistant Prostate Cancer},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {8},
pages = {1241},
doi = {10.3390/ph18081241}
}
EUVIMED